Pfizer launching new drug Suspiciously Similar To Ivermectin

[Funnywhensunny]

NY Times Casually Admits New FDA-Approved Merck COVID Drug Might Actually Mutate Healthy Human DNA by Accident and Impact Male Fertility | The Gateway Pundit | by Jim Hoft

In normal times, in a normal world, this news might make headlines.

www.thegatewaypundit.com

Thank you for keeping us posted on this stuff, Pina.

 

[Peatness]

Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1)

As much as people are justifiably excited about the prospect for orally available drugs that can prevent and treat Covid-19, I believe the FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval.

www.forbes.com

Harming Those Who Receive It: The Dangers Of Molnupiravir (Part 2)

Molnupiravir may also be a danger to those who receive the drug as a treatment, potentially causing cancerous tumors and birth defects.

www.forbes.com

https://newsforward.org/supercharging-new-viral-variants-the-dangers-of-molnupiravir

 

[Peatness]

Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1)

As much as people are justifiably excited about the prospect for orally available drugs that can prevent and treat Covid-19, I believe the FDA needs to tread very carefully with molnupiravir, the antiviral currently before them for approval.

www.forbes.com

Harming Those Who Receive It: The Dangers Of Molnupiravir (Part 2)

Molnupiravir may also be a danger to those who receive the drug as a treatment, potentially causing cancerous tumors and birth defects.

www.forbes.com

https://newsforward.org/supercharging-new-viral-variants-the-dangers-of-molnupiravir

The latest on molnupiravir

https://maryannedemasi.com/publications/f/warning-for-molnupiravir-despite-green-light-from-drug-regulators

From the article

The UK regulator was the first to grant “conditional marketing approval” for molnupiravir, with Health Secretary Sajid Javid publicly boasting it was an “historic day” for his country, and that the drug would be a “game-changer” and “ground-breaking.”
This was all before the completion of the trial. In the weeks that followed, American, Japanese, and Australian drug regulators, all gave their stamp of approval after the phase III trial was complete.
In Australia for example, GPs may now prescribe molnupiravir for COVID-positive adults at high risk of developing severe disease, and the cost is largely subsidised by the government.
But not everyone is enamoured with the drug. France cancelled its order and there are now reports that Merck is struggling to win approval in Europe and Canada, because the data are proving to be “problematic” according to those familiar with the process.
As more data emerges, some experts warn against the use of molnupiravir, citing concerns over the drug’s clinical value and its safety.